Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 32INDUSTRY 9NETWORK 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Kidney Neoplasms 1Clear-cell metastatic renal cell carcinoma 1

Interventions

bicalutamide 23Radiotherapy 21Goserelin 21Docetaxel 19Flutamide 17Leuprolide 16Prednisone 11Radiotherapy, Conformal 10Gonadotropin-Releasing Hormone 10Radiotherapy, Intensity-Modulated 9Triptorelin Pamoate 8Buserelin 8Estramustine 7Androgen Antagonists 7Brachytherapy 6luprolide acetate gel depot 5enzalutamide 5Paclitaxel 5nilutamide 4darolutamide 4acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 4Radiation 4Mitoxantrone 4Carboplatin 4orteronel 3apalutamide 3Selenium 3Orchiectomy 3Magnetic Resonance Spectroscopy 3Iodine-125 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Prostatic Neoplasms × Pluvicto × Clear all
NCT04663997 2026-03-27

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Canadian Cancer Trials Group

Phase 2 Active not recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡